ICIs that are neutralizing antibodies against CTLA-4 and PD-1 can activate the anti-tumor immune response and inhibit the growth of tumor cells by blocking the negative inhibitory effect of PD-1 and CTLA-4 on T cells. This evidence concerns the gene PDCD1 and neoplasm.